Education
About Us
Working with TipRanks
Follow Us
Novartis AG (CH:NOVN)
:NOVN
Earnings Data
Report Date
Apr 28, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
1.66Last Year’s EPS
1.77Same Quarter Last Year
Moderate Buy
Based on 13 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Overall the call is Positive. Novartis reported strong full-year execution — record free cash flow, achievement of a 40.1% core margin two years early, multiple blockbuster product performances, and meaningful pipeline progress with numerous upcoming pivotal readouts. Near-term headwinds are material (largest-ever generic/patent expiries in 2026, Q4 gross-to-net and LOE impacts, Avidity-related margin dilution, and some trial uncertainties such as lower-than-expected event rates for pelacarsen and limited FDA-requested liver monitoring for remibrutinib). Management provided a cautious 2026 outlook (H1 weakness, full-year low-single-digit sales growth) but reiterated mid-term confidence (5%–6% CAGR to 2030 and return to 40%+ margin by 2029). Taken together, the positives around cash generation, portfolio momentum and pipeline execution outweigh the near-term operational and regulatory challenges.Company Guidance
Full-Year Sales and Margin Achievement
Full-year 2025 sales grew 8% (high single-digit). Core operating income rose 14% and Novartis achieved a 40.1% core margin (target reached two years early). Core operating income reached approximately $21.9 billion.
Record Free Cash Flow and EPS Growth
Free cash flow reached an all-time high of $17.6 billion (up 8% year-over-year). Core EPS increased 17% to $8.98.
Strong Performance from Priority Brands
Multiple priority brands delivered high growth: Kisqali up 57% (FY) to $4.8B with 44% Q4 growth (54% excluding U.S. RD adjustments, U.S. 62%); Kesimpta up 36% to $4.4B; Scemblix reached blockbuster status with 87% Q4 growth and 41% NBRx share; Pluvicto grew 42% constant currency to $2B (U.S. pre-taxane sales +75%); Leqvio grew 57% FY (46% Q4) and reached blockbuster status; Cosentyx grew 8% to $6.7B.
Pluvicto and RLT Scale-up
Pluvicto showed dynamic uptake (PSMAfore launch) with PSMA share of 16% in the setting and over 790 treatment sites in the U.S.; new manufacturing sites coming online (California, Florida, Japan, China) to expand capacity for radioligand therapy launches.
Successful New Product Launches and Early Commercial Momentum
Rhapsido U.S. launch showed encouraging early results with >2,000 HCP starts in sampling/bridge program and strong demand from allergists/dermatologists; Itvisma (gene therapy) approved in U.S. with broad label and multi-blockbuster potential estimated >$3B.
Pipeline Progress and Pivotal Readouts
Met the majority of 2025 R&D milestones and positioned for seven pivotal readouts in 2026 (pelacarsen, remibrutinib, ianalumab, DUX4 interim, others), demonstrating active pipeline execution and replacement power for future growth.
Pelabresib MANIFEST Results and Regulatory Path
Pelabresib Phase III 96-week MANIFEST data showed deep, durable spleen responses, sustained symptom and anemia improvements, comparable safety to ruxolitinib and fewer deaths/progressions; agreement with EU to file in 2026 and plan for new Phase III in U.S./China/Japan.
Capital Allocation and Shareholder Returns
Completed $15B buyback in early July and launched a new up-to-$10B program (≈$7.7B remaining). Proposed dividend CHF 3.70 per share (6% increase in CHF, double-digit in USD), continuing long track record of dividend growth. R&D investment >$10B (+8% YOY).
Long-Term Growth Confidence
Company reaffirmed 5%–6% sales CAGR for 2025–2030 and expects to return to 40%+ core margin by 2029, signaling confidence in mid-term trajectory despite near-term headwinds.
CH:NOVN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CH:NOVN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 04, 2026 | CHF116.88 | CHF118.70 | +1.56% |
Oct 28, 2025 | CHF103.16 | CHF98.87 | -4.16% |
Jul 17, 2025 | CHF95.12 | CHF93.34 | -1.87% |
Apr 29, 2025 | CHF93.40 | CHF94.21 | +0.87% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Novartis AG (CH:NOVN) report earnings?
Novartis AG (CH:NOVN) is schdueled to report earning on Apr 28, 2026, TBA (Confirmed).
What is Novartis AG (CH:NOVN) earnings time?
Novartis AG (CH:NOVN) earnings time is at Apr 28, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Novartis AG stock?
The P/E ratio of Novartis AG is N/A.
What is CH:NOVN EPS forecast?
CH:NOVN EPS forecast for the fiscal quarter 2026 (Q1) is 1.66.